Hjem › Plateepitelcancer i hode og hals › Maryland
Kliniske studier for Plateepitelcancer i hode og hals i Maryland
18 studier for Plateepitelcancer i hode og hals søker deltakere på steder i Maryland.
Byer i Maryland
Offisiell studietekst (engelsk)
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Site #0112, Baltimore
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06788990Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #14, Baltimore
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT05176483Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- University of Maryland/Greenebaum Cancer Center, Baltimore
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06589804A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- University of Maryland Greenebaum Cancer Center, Baltimore
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07276399A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- University of Maryland School of Medicine, Baltimore
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06385080Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Central Maryland Radiation Oncology in Howard County, Columbia
- UM Baltimore Washington Medical Center/Tate Cancer Center, Glen Burnie
RekruttererFase 2
Alder 18 til 79 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT04671667Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
- National Institutes of Health Clinical Center, Bethesda
RekruttererFase 2
Alder 18 til 120 · Alle kjønn · Oppdatert 18. sep. 2026 · NCT06161545Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- Greater Baltimore Medical Center, Baltimore
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT02734537Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
- Research Site, Baltimore
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. sep. 2026 · NCT06535607A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
- University of Maryland, Baltimore
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06163534Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- Greater Baltimore Medical Center, Baltimore
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT06532279Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- Johns Hopkins Hospital /ID# 254056, Baltimore
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 4. jun. 2026 · NCT04777994A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- GSK Investigational Site, Columbia
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 26. mai 2026 · NCT06256588DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA11-0, Bethesda
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. mai 2026 · NCT06953089A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- University of Maryland, Baltimore
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 9. apr. 2026 · NCT06064877A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 13. feb. 2026 · NCT06778863Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
- Maryland Proton Treatment Center, Baltimore
- University of Maryland Greenebaum Cancer Center, Baltimore
- Upper Chesapeake Health, Bel Air
- og 2 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 10. nov. 2025 · NCT06088381A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 4. nov. 2025 · NCT05902988Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.